Probiotics for Ulcerative Colitis
Verdict: Published with Warning
Across 6 PubMed studies, the evidence for Probiotics in Ulcerative Colitis grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.61
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
84%
Highly consistent evidence
Evidence level
E1
Cochrane high-quality SR/MA
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.613
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (2 negative > 0 positive)，下層 RCT 不能推翻
- apply_hec_override — HEC-1 高階證據 negative — 強制由 B 改為 D
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Probiotics for induction of remission in ulcerative colitis
Finding: Probiotics may induce clinical remission vs placebo (RR 1.73, 95% CI 1.19-2.54; 9 trials, 594 pts, NNTB 5) but show little or no difference vs 5-ASA (RR 0.92, 95% CI 0.73-1.16), all on low-certainty evidence.
View on PubMed Probiotics for maintenance of remission in ulcerative colitis
Finding: No clear benefit: clinical relapse vs placebo RR 0.87 (95% CI 0.63-1.18, NS) and maintenance of remission RR 1.16 (95% CI 0.98-1.37, NS); effectiveness 'remains unclear' on low- to very-low-certainty evidence.
View on PubMed Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease
Finding: No overall benefit of probiotics over placebo for inducing remission in active UC (RR of failure 0.86, 95% CI 0.68-1.08), but VSL#3 alone was effective (RR 0.74, 95% CI 0.63-0.87) and probiotics were equivalent to 5-ASA for preventing relapse (RR 1.02, 95% CI 0.85-1.23).
View on PubMed Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
Finding: Over 12 months relapse occurred in 36.4% (40/110) of the Nissle group vs 33.9% (38/112) of the mesalazine group, meeting the prespecified equivalence criterion (p=0.003) with comparable safety.
View on PubMed The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis
Finding: VSL#3 outperformed placebo on the primary surrogate endpoint (>=50% UCDAI drop at 6 wks: 32.5% vs 10%, P=0.001) and on clinical remission at 12 weeks (42.9% vs 15.7%, P<0.001).
View on PubMed Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study
Finding: VSL#3 met the primary surrogate endpoint (>=50% UCDAI drop 63.1% vs 40.8%, ITT P=0.031) but the clinical remission endpoint did NOT reach significance (47.7% vs 32.4%, ITT P=0.132).
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
FDA has not approved any probiotic product for use as a drug or biological product in infants of any age source↗
L4b EU EFSA
Against
a cause and effect relationship had not been established between the consumption of a combination of bacterial strains and reduction of gastro-intestinal discomfort source↗
L4c UK NHS
Cautious
There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. source↗
L4d TW TFDA / 衛福部
Supportive
益生菌屬食品，並無治療疾病的效果 source↗
L4e WHO
Neutral
probiotic supplementation with the strains Bifidobacterium longum subsp. Infantis DSM33361 and Lactobacillus rhamnosus GG source↗
L5a NIH Office of Dietary Supplements
Supportive
Probiotics might reduce some symptoms of IBS. source↗
L5b Mayo Clinic
Cautious
Many people assume probiotic supplements will fix the gut microbiome, but evidence is mixed, and the American Gastroenterological Association does not recommend probiotic supplements for treating ulcerative colitis in most situations. However, they should be treated like medicine and discussed with your healthcare professional before use. source↗
L5c Cleveland Clinic
Cautious
An unhealthy gut microbiome — one in which harmful microbes outnumber the helpful types — can contribute to a variety of chronic gastrointestinal diseases, including inflammatory bowel diseases, like ulcerative colitis and Crohn's disease. Taking oral probiotics might help prevent or treat these conditions, although results may vary. source↗
L5d Harvard Health
Cautious
Some studies suggest that certain bacterial strains, such as Bifidobacteria and Lactobacilli, are somewhat effective for ulcerative colitis, reducing symptoms, promoting remission, and improving quality of life. But these effects are modest compared to standard therapies, and probiotics have not shown enough benefit to be accepted in medical practice. source↗
L5e Specialty Society (condition-mapped)
Cautious
Two probiotics called Visbiome (formerly VSL #3) and E. Coli Nissle 1917 may help people with Ulcerative Colitis. source↗